Trade Bure Equity AB - Bure Equity
Bure Equity is a situation-based investment company. It was founded in 1992 with the abolition of Sweden’s wage-earner funds. Over its 25-year history, Bure Equity has built a diversified portfolio, comprised of nine companies. The listed companies are the Cavotec engineering group, the MedCap investor in the Life Science sector, the Mycronic electronics designer, the Vitrolife medtech group, and the Xvivo Perfusion medtech company, specialising in transplantation. The Bure Equity unlisted holdings include Bure Financial Services, Bure Growth, Investment AB Bure, and Mercuri International. The Bure Equity group has traded on the NASDAQ Stockholm since 1993. The company’s share price is listed under the BURE ticker in the Mid Cap list. Follow the latest Bure Equity share price trends at Capital.com.Latest shares articles

BAE Systems stock forecast: H1 results, guidance upgrade
BAE Systems is a UK defence and aerospace group listed in London. In August 2026, it secured a $149.8m US Navy award for work on the USS Boxer. Explore third-party BA. price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:18, 16 October 2026

TAURON stock forecast: H1 earnings
TAURON is a Polish energy group. In the first half of 2026, revenue was broadly flat, while EBITDA and net profit fell amid higher CO2 allowance costs and coal consumption. Explore third-party analyst targets and technicals. Past performance is not a reliable indicator of future results.
12:04, 12 October 2026

Puma stock forecast: Anta stake deal cleared
Puma is a German sportswear company. Chinese regulators have cleared Anta Sports’ proposed acquisition of an approximately 29% stake, with completion expected before the end of 2026. Explore third-party PUM price targets. Past performance is not a reliable indicator of future results.
10:19, 12 October 2026

Dino Polska stock forecast: H1 sales growth slows
Dino Polska is a Polish grocery retailer. In H1 2026, revenue rose 12.5% year on year to 18.0bn PLN, while like-for-like sales growth slowed to 2.2%. Explore third-party DNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
08:27, 12 October 2026
Related News